These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32956576)

  • 1. A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation.
    Nickerson PW; Balshaw R; Wiebe C; Ho J; Gibson IW; Bridges ND; Rush DN; Heeger PS
    Am J Transplant; 2021 Apr; 21(4):1503-1512. PubMed ID: 32956576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial.
    Stock PG; Mannon RB; Armstrong B; Watson N; Ikle D; Robien MA; Morrison Y; Odorico J; Fridell J; Mehta AK; Newell KA
    Am J Transplant; 2020 Jun; 20(6):1668-1678. PubMed ID: 32039559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
    de Fijter JW; Holdaas H; Øyen O; Sanders JS; Sundar S; Bemelman FJ; Sommerer C; Pascual J; Avihingsanon Y; Pongskul C; Oppenheimer F; Toselli L; Russ G; Wang Z; Lopez P; Kochuparampil J; Cruzado JM; van der Giet M;
    Am J Transplant; 2017 Jul; 17(7):1853-1867. PubMed ID: 28027625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
    Gaston RS; Kaplan B; Shah T; Cibrik D; Shaw LM; Angelis M; Mulgaonkar S; Meier-Kriesche HU; Patel D; Bloom RD
    Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
    Su L; Tam N; Deng R; Chen P; Li H; Wu L
    Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
    J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation.
    Gottlieb J; Neurohr C; Müller-Quernheim J; Wirtz H; Sill B; Wilkens H; Bessa V; Knosalla C; Porstner M; Capusan C; Strüber M
    Am J Transplant; 2019 Jun; 19(6):1759-1769. PubMed ID: 30615259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
    Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
    Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
    Budde K; Zeier M; Witzke O; Arns W; Lehner F; Guba M; Jacobi J; Kliem V; Reinke P; Hauser IA; Vogt B; Stahl R; Rath T; Duerr M; Paulus EM; May C; Porstner M; Sommerer C;
    Nephrol Dial Transplant; 2017 Jun; 32(6):1060-1070. PubMed ID: 28605781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation.
    Alloway RR; Woodle ES; Abramowicz D; Segev DL; Castan R; Ilsley JN; Jeschke K; Somerville KT; Brennan DC
    Am J Transplant; 2019 Aug; 19(8):2252-2261. PubMed ID: 30838775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.